13F Holdings
中文EN

MDLN Medline Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 2046386 · Fiscal year ends 12/31

Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin25.7%
Operating margin5.7%
Net margin1.9%
FCF margin6.2%
EBITDA margin9.0%

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets51.7%
Debt / equity1.07x
Current ratio4.04x
Interest coverage2.50x

Cash quality & payout

Operating cash flow / net income4.13x
Accruals ratio—
Payout ratio—
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY2025*2025-12-16FY2024*2024-12-31FY2023*2023-12-31
Income statement
Revenue$28.43B—$25.51B$23.23B
Cost of revenue$20.91B—$18.53B$17.35B
Gross profit$7.52B—$6.98B$5.88B
R&D expense$80.00M—$67.00M$60.00M
SG&A expense$4.52B—$4.11B$3.87B
Operating income$2.21B—$2.15B$1.25B
Interest expense$945.00M—$1.14B$1.21B
Pretax income$1.25B—$1.25B$264.00M
Income tax$91.00M—$46.00M$30.00M
Net income$1.16B$1.15B$1.16B$234.00M
EBITDA$3.22B—$3.12B$2.20B
EPS (basic)-0.01———
EPS (diluted)-0.01———
Weighted avg. shares (diluted)810.00M———
Balance sheet
Cash & equivalents$1.94B—$250.00M$1.58B
Short-term investments$0———
Receivables$3.53B—$3.22B—
Inventory$4.77B—$4.46B—
Current assets$10.68B—$8.27B—
PP&E, net$4.78B—$4.59B—
Goodwill$8.08B—$8.06B$7.53B
Intangibles$13.89B—$14.56B—
Total assets$38.48B—$35.98B—
Current liabilities$2.49B—$2.44B—
Short-term debt$77.00M—$78.00M—
Long-term debt$12.48B—$16.42B—
Total debt$12.56B—$16.49B—
Total liabilities$19.20B—$19.45B—
Shareholders' equity$10.74B———
Net debt$10.62B—$16.24B—
Cash flow statement
Operating cash flow$1.74B—$1.77B$1.69B
Capital expenditure$447.00M—$354.00M$275.00M
Free cash flow$1.30B—$1.42B$1.41B
Investing cash flow-$474.00M—-$1.49B-$312.00M
Financing cash flow$399.00M—-$1.61B-$191.00M
Depreciation & amortization$1.01B—$977.00M$951.00M
Stock-based compensation$76.00M—$61.00M$78.00M
Share buybacks$33.00M—$20.00M$0

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.